CLRB — Cellectar Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$2.46
-$0.05 (-1.99%)
Cellectar Biosciences Inc (CLRB) is a biotechnology company listed on NASDAQ. It is led by James V. Caruso, based in 100 Campus Drive, Florham Park, NJ, United States, 07932, with about 11 employees. Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Net income was -$4.4M. CLRB currently screens at market cap $20.8M.
Use this CLRB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CLRB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CLRB SEC filings page. Lician reads the product cache first so this HTML stays unique to Cellectar Biosciences Inc even when a live quote feed is slow.
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB Key Statistics
Market Cap
$20.78M
Volume
6,919
Previous Close
$2.52
Day Range
$2.52 – $2.60
EPS
-$1.40
Revenue
$0.00
Net Income
-$44.58M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
11
CLRB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$44.58M | -$42.77M | -$28.60M | -$24.12M |
| EPS (Diluted) | -$1.40 | -$3.50 | -$4.05 | -$4.35 |
Total Assets
$25.47M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$23.29M
Operating Cash Flow
-$47.58M
Free Cash Flow
$0.00
Cellectar Biosciences Inc Company Information
- President, CEO & Director
- James V. Caruso
- Headquarters
- 100 Campus Drive, Florham Park, NJ, United States, 07932
- Website
- www.cellectar.com
- Phone
- 608 441 8120
- IPO / Founded
- 2005-11-10
- Sector
- Healthcare
- Industry
- Biotechnology